Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Electronic Site License Enterprisewide ADME in Children and The Elderly: Clinical Challenges and Opportunities Drug and Market Development Publishing, Oct 2005, Pages: 162   Description     Table of Contents     Summary     Companies Mentioned        Enquire before Buying    Send to a Friend   The elderly represent an increasingly important pharmaceutical market, for demographic reasons. For example, in the UK 18% of the population is over 65 years of age, but account for 45% of drug dispensing. Older patients tend to suffer from diseases such as liver and kidney impairment that require concurrent medications that modify the ADME profile. Planning and executing pharmacokinetic studies in both the elderly and pediatric population can be problematic. For example, studies that enroll children need to examine the drugs' effect on some specific parameters, such as skeletal growth and other developmental aspects including psychomotor milestones. Understanding the cases of these age-related changes, being able to quantify the effect and predict the potential outcomes is rapidly become a core competency for companies interested in exploiting the commercial opportunities that emerge from a graying population. At least 95% of new drugs and biopharmaceuticals show a poor PK profile and other properties that could undermine profitability. ADME is the key for ensuring efficacy and tolerability. However, many drugs still fail due to poor ADME. This report examines the latest research on the causes and consequences of ADME changes in the elderly and children. Commercial considerations such as market size, demographics, and the impact of ADME on the cost of drug development are thoroughly discussed. In addition, age related changes in ADME and in silico ADME profiles are detailed. The Report features exclusive interviews with key opinion leaders in the ADME arena as well as relevant case studies. Questions Answered - What are sources of age related ADME changes in the elderly? - What are sources of age related ADME changes in children? - What are the commercial considerations of ADME in children and the elderly? - What are the pressing issues for future research in this area? - What is the impact of ADME evaluation on the cost of drug development? - How will the discipline of ADME develop over the next five to ten years? - How can the value of ADME modeling in drug discovery be optimized? - Who are the key players in this space? Product samples Chapter 4 - Age Related Changes in ADME Sample Company Profile - GeneGo Inc Customers who bought this item also bought Adme/Tox Technologies Repositioning ADME Studies: A Strategy to Reduce Drug Attrition Drug Transporters and ADME: Pharmacological and Commercial Implications Predictive ADME and Toxicology Strategies: Challenges and Opportunities for In Vivo, In Vitro and In Silico Predictive Technologies World ADME/Tox in Drug Development Markets Strategic Analysis of the ADME/TOX Technologies Market in Europe A Survey of ADME-TOX Trends in Drug Development U.S. ADME/Tox in Drug Development Markets Mass Spectrometry in Drug Metabolism and Pharmacokinetics In Silico ADME/Tox Products Market 2006 Prescribing for Elderly Patients Human Drug Metabolism: An Introduction

		Top of page

All rights reserved. � Copyright 2009 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster